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In their study of natural killer (NK) cell activity with tumor cell
targets from cutaneous T cell lymphoma (CTCL) patients,
our French colleagues have probed the immunologic un-
derpinnings of several distinctive clinical features of these
lymphomas (Bouaziz et al, 2005). The fascination of the
French with this group of disorders is a notable legacy, with
contributions from Alibert, Bazin, and Sezary. Sezary syn-
drome patients were the focus of this study and it is fitting
that the authors pursue the demise of Sezary’s original pa-
tients—death by infection. The immune failure in Sezary
syndrome and in CTCL is clinically relevant. Patients with
this disorder develop second malignancies (Olsen et al,
1984; Kantor et al, 1989), succumb to bacterial infections
and septicemia (Posner et al, 1981), and suffer from un-
controlled viral infections (Masessa et al, 1989) while their
physicians frantically seek to reverse the immune failure. We
can describe the components of the immune collapse. One
unique feature is that as the malignant T cell clone expands,
it does so at the expense of normal T cells, creating an
immunodeficiency in numbers of cells that can be assessed
by molecular (Kono et al, 1992) or flow cytometric (Heald
et al, 1994) techniques.
The unique immunocompromise that plays such a pivotal
role in the demise of patients with CTCL is a target for
therapy. In this group of disorders a patient may benefit
from extracorporeally damaging a small portion of the
malignant cell pool followed by reinfusion of those cells
(photopheresis). Other immunoenhancing modalities have
included injections of interferon, injections of DNA vaccines,
injections of bacterial DNA sequences, and the ultimate in
immunotherapy—allogeneic stem cell transplantation. The
paper in this issue of the Journal demonstrates that cultured
or recently harvested CTCL cells are appropriate targets for
NK cell-mediated lysis. If this mechanism plays a role in the
tumor surveillance of CTCL, then the work would imply the
escape from control is not on the basis of evading NK cell-
mediated lysis. The finding that allogeneic NK cells could
lyse patient-derived CTCL cells is significant in terms of the
growing role of allotransplantation in the management of
CTCL (Soligo et al, 2003). Previous attempts to utilize bone
marrow transplantation were primarily designed to use the
allograft as a way to survive the upper echelons of a
chemotherapeutic’s dose–response curve. Those attempts
were marked by failure and relapse. The novel approach of
a mini-transplant is designed to utilize graft versus host
disease as the major therapy instead of high dose chem-
otherapy. The results of this type of transplantation have
been encouraging (Soligo et al, 2003), and probably these
results reflect the ability of donor-derived NK cells to sim-
ilarly lyse recipient-derived CTCL cells.
One of the more intriguing observations is that the au-
tologous cytotoxicity assays demonstrated that patient-
derived NK cells had the ability to specifically lyse patient-
derived CTCL cells. Again, this fledgling anti-tumor re-
sponse is probably the mechanism that so many immuno-
modulating measures (mentioned above) are trying to
enhance and activate. But is the failure of this tumor sur-
veillance the reason why patients have the disease? Is the
root cause in the inability of these cells to do in vivo what
they can in vitro? Or is the ineffectiveness of this mecha-
nism a side effect of the progressive lymphoma, like smoke
is to fire? These questions are raised by this provocative
work.
Further studies spurred by this paper would lead in two
directions. Specific modulation of the NK cell activity
against the CTCL cells will open the door to more specific
immunotherapies than those currently available. But the
more intriguing answers will come from the dissection of the
molecular targets that sit in the Class I MHC that underly the
NK lysis function. Understanding the mechanisms of the
specificity of cell lysis will lead to improved specificity of
therapeutic maneuvers. Controlling this mechanism would
benefit many patients other than the few who suffer pro-
gressive cutaneous lymphomas. These lessons would read-
ily be applicable to other tumors, many of which already
plague CTCL patients (Olsen et al, 1984; Kantor et al, 1989)
because of the failure of NK-mediated tumor surveillance.
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